A Phase 3 interventional study of Antidepressant + SPD489 (Lisdexamfetamine dimesylate ) and Antidepressant + Placebo in Major Depressive Disorder, sponsored by Shire. Completed at 101 sites in 11 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-06-09.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Depressive Disorder, Major by Takeda — 1 open to participants now, 1 under way, 1 of them phase 3. Depressive Disorder, Major · Takeda.
Among the 26 studies in Depressive Disorder, Major by Takeda, this one is the 5th largest by enrollment of the 24 interventional ones that give a count, is one of 6 that started in 2011, is one of 16 in phase 3, and was the 15th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 26 studies in Depressive Disorder, Major by Takeda is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 17 · Phase 4 3
First in 2008; this study’s year is marked. 6 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,105 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 580 across the 24 interventional studies, 73,904 across the 2 observational. Of the 25 that completed or were terminated, 24 (96%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Depressive Disorder, Major by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. Eligible patients will remain on their antidepressant but will be randomized to either receive supplemental SPD489 or placebo (i.e. sugar pill). The purpose of this study is to help answer the following questions:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate )
Drug: Antidepressant + Placebo
Drug page: Lisdexamfetamine
Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
Also known as: Vyvanse
Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 8 Weeks
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.
Time frame: 8 weeks
Mean Change From Baseline in Sheehan Disability Scale (SDS) Total Score at 8 Weeks
Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work/school, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment.
Time frame: 8 weeks
Percentage of Participants Achieving a 25% Response on the MADRS
The percentage of subjects who achieved a 25% response (i.e. ≥25% reduction in MADRS total score from the Lead-in Baseline, Visit 2).
Time frame: Up to 8 weeks
Percentage of Participants Achieving a 50% Response on the MADRS
The percentage of subjects who achieved a 50% response (i.e. ≥50% reduction in MADRS total score from the Lead-in Baseline, Visit 2).
Time frame: Up to 8 weeks
Percent of Participants Achieving Remission on the MADRS
MADRS remission was defined as a MADRS total score of ≤10.
Time frame: Up to 8 weeks
Mean Change From Baseline Over Time in MADRS Total Score
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.
Time frame: Up to 8 weeks
Mean Change From Baseline in Abbreviated Brief Assessment of Cognition Affective Disorders (ABAC-A) Composite T-Scores
The ABAC-A is a rater-administered series of activities designed to be sensitive to the critical cognitive deficits in affective disorders and schizophrenia. There are 6 subtests of the ABAC-A: List Learning (verbal memory); Digit Sequencing Task (working memory); Token Motor Task (motor speed); Verbal Fluency; Symbol Coding (attention and processing speed); and Tower of London Test (executive functions). The ABAC-A Composite T-score change from Augmentation Baseline Visit (Visit 8; Week 8) at Visit 14/Early Termination (ET) (Week 16/ET) was analyzed.
Time frame: up to 8 weeks
Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2)
Total score ranges from 0 (lowest level of health) - 100 (highest level of health) on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability (i.e. a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability). Higher scores are associated with better quality of life.
Time frame: Up to 8 weeks
Mean Change in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score Male
The CSFQ-14 is a short-form interview/questionnaire that measures illness- and medication-related changes in sexual functioning. A 5-point Likert scale is used ranging from 1 (never) to 5 (always). The CSFQ-14 total score can range from 14 to 70, with lower scores being associated with worsened sexual functioning.
Time frame: Up to 8 weeks
Mean Change in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score Female
The CSFQ-14 is a short-form interview/questionnaire that measures illness- and medication-related changes in sexual functioning. A 5-point Likert scale is used ranging from 1 (never) to 5 (always). The CSFQ-14 total score can range from 14 to 70, with lower scores being associated with worsened sexual functioning.
Time frame: Up to 8 weeks
Clinical Global Impressions - Global Improvement (CGI-I)
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
Time frame: Up to 8 weeks
Mean Change From Baseline in the Multidimensional Assessment of Fatigue (MAF) Global Fatigue Index (GFI)
MAF contains 16 items scored on a scale from 1 (not at all) to 10 (a great deal). Answers are converted to a Global Fatigue Index with total scores ranging from 1 (no fatigue) to 50 (severe fatigue). Lower scores indicate less fatigue.
Time frame: Up to 8 weeks
Columbia Suicide Severity Rating Scale (C-SSRS)
C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.
Time frame: Up to 8 weeks
Amphetamine Cessation Symptom Assessment (ACSA) - Total Aggregate Score
ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.
Time frame: 8 weeks
| Milestone | Antidepressant + Single-blind Placebo | Antidepressant + Double-blind SPD489 | Antidepressant + Double-blind Placebo |
|---|---|---|---|
| Started | 1105 | 0 | 0 |
| Completed | 823 | 0 | 0 |
| Not completed | 282 | 0 | 0 |
| Withdrew: Adverse event | 26 | 0 | 0 |
| Withdrew: Protocol violation | 24 | 0 | 0 |
| Withdrew: Withdrawal by subject | 69 | 0 | 0 |
| Withdrew: Lost to follow-up | 43 | 0 | 0 |
| Withdrew: Met bp or pulse withdrawal criteria | 13 | 0 | 0 |
| Withdrew: Other | 107 | 0 | 0 |
| Milestone | Antidepressant + Single-blind Placebo | Antidepressant + Double-blind SPD489 | Antidepressant + Double-blind Placebo |
|---|---|---|---|
| Started | 397 | 212 | 214 |
| Completed | 353 | 181 | 189 |
| Not completed | 44 | 31 | 25 |
| Withdrew: Adverse event | 1 | 5 | 6 |
| Withdrew: Protocol violation | 4 | 4 | 2 |
| Withdrew: Withdrawal by subject | 16 | 9 | 8 |
| Withdrew: Lost to follow-up | 17 | 5 | 4 |
| Withdrew: Lack of efficacy | 0 | 1 | 1 |
| Withdrew: Met bp or pulse withdrawal criteria | 4 | 2 | 0 |
| Withdrew: Other | 2 | 5 | 4 |
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.
| units on a scale | Antidepressant + SPD489 | Antidepressant + Placebo |
|---|---|---|
| Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 8 Weeks | -7.3 (-8.6 to -6.0) | -6.8 (-8.1 to -5.5) |
Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work/school, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment.
| units on a scale | Antidepressant + SPD489 | Antidepressant + Placebo |
|---|---|---|
| Mean Change From Baseline in Sheehan Disability Scale (SDS) Total Score at 8 Weeks | -4.9 (-5.8 to -4.0) | -4.3 (-5.2 to -3.4) |
The percentage of subjects who achieved a 25% response (i.e. ≥25% reduction in MADRS total score from the Lead-in Baseline, Visit 2).
| percentage of participants | Antidepressant + SPD489 | Antidepressant + Placebo |
|---|---|---|
| Percentage of Participants Achieving a 25% Response on the MADRS | 68.9 | 74.2 |
The percentage of subjects who achieved a 50% response (i.e. ≥50% reduction in MADRS total score from the Lead-in Baseline, Visit 2).
| percentage of participants | Antidepressant + SPD489 | Antidepressant + Placebo |
|---|---|---|
| Percentage of Participants Achieving a 50% Response on the MADRS | 41.6 | 37.1 |
MADRS remission was defined as a MADRS total score of ≤10.
| percentage of participants | Antidepressant + SPD489 | Antidepressant + Placebo |
|---|---|---|
| Percent of Participants Achieving Remission on the MADRS | 23.0 | 17.8 |
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.
| units on a scale | Antidepressant + SPD489 | Antidepressant + Placebo |
|---|---|---|
| Week 9 (Visit 9) | -2.9 (-3.9 to -2.0) | -2.1 (-3.0 to -1.1) |
| Week 10 (Visit 10) | -4.4 (-5.5 to -3.3) | -4.3 (-5.4 to -3.2) |
| Week 11 (Visit 11) | -5.9 (-7.1 to -4.7) | -5.0 (-6.2 to -3.8) |
| Week 12 (Visit 12) | -6.3 (-7.6 to -5.1) | -5.3 (-6.5 to -4.1) |
| Week 14 (Visit 13) | -6.9 (-8.2 to -5.5) | -6.4 (-7.7 to -5.1) |
| Week 16 (Visit 14) | -7.3 (-8.6 to -6.0) | -6.8 (-8.1 to -5.5) |
The ABAC-A is a rater-administered series of activities designed to be sensitive to the critical cognitive deficits in affective disorders and schizophrenia. There are 6 subtests of the ABAC-A: List Learning (verbal memory); Digit Sequencing Task (working memory); Token Motor Task (motor speed); Verbal Fluency; Symbol Coding (attention and processing speed); and Tower of London Test (executive functions). The ABAC-A Composite T-score change from Augmentation Baseline Visit (Visit 8; Week 8) at Visit 14/Early Termination (ET) (Week 16/ET) was analyzed.
| t-score | Antidepressant + SPD489 | Antidepressant + Placebo |
|---|---|---|
| Mean Change From Baseline in Abbreviated Brief Assessment of Cognition Affective Disorders (ABAC-A) Composite T-Scores | 3.0 (2.1 to 4.0) | 2.5 (1.5 to 3.5) |
Total score ranges from 0 (lowest level of health) - 100 (highest level of health) on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability (i.e. a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability). Higher scores are associated with better quality of life.
| units on a scale | Antidepressant + SPD489 | Antidepressant + Placebo |
|---|---|---|
| Physical | 1.07 (0.04 to 2.10) | 0.90 (-0.11 to 1.91) |
| Mental | 6.63 (5.03 to 8.23) | 5.16 (3.60 to 6.73) |
The CSFQ-14 is a short-form interview/questionnaire that measures illness- and medication-related changes in sexual functioning. A 5-point Likert scale is used ranging from 1 (never) to 5 (always). The CSFQ-14 total score can range from 14 to 70, with lower scores being associated with worsened sexual functioning.
| units on a scale | Antidepressant + SPD489 | Antidepressant + Placebo |
|---|---|---|
| Mean Change in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score Male | 2.1 ± 6.22 | 1.0 ± 6.02 |
The CSFQ-14 is a short-form interview/questionnaire that measures illness- and medication-related changes in sexual functioning. A 5-point Likert scale is used ranging from 1 (never) to 5 (always). The CSFQ-14 total score can range from 14 to 70, with lower scores being associated with worsened sexual functioning.
| units on a scale | Antidepressant + SPD489 | Antidepressant + Placebo |
|---|---|---|
| Mean Change in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score Female | 3.0 ± 7.11 | 1.9 ± 5.82 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
| percentage of participants | Antidepressant + SPD489 | Antidepressant + Placebo |
|---|---|---|
| Improved | 56.9 | 53.5 |
| Not Improved | 43.1 | 46.5 |
| Not Assessed | 0 | 0 |
MAF contains 16 items scored on a scale from 1 (not at all) to 10 (a great deal). Answers are converted to a Global Fatigue Index with total scores ranging from 1 (no fatigue) to 50 (severe fatigue). Lower scores indicate less fatigue.
| units on a scale | Antidepressant + SPD489 | Antidepressant + Placebo |
|---|---|---|
| Mean Change From Baseline in the Multidimensional Assessment of Fatigue (MAF) Global Fatigue Index (GFI) | -6.6 ± 0.74 | -4.4 ± 0.73 |
C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.
| percentage of participants | Antidepressant + SPD489 | Antidepressant + Placebo |
|---|---|---|
| ≥1 positive suicidal ideation | 9.0 | 9.4 |
| ≥1 suicidal attempt | 0 | 0.5 |
ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.
| Score | Antidepressant + SPD489 | Antidepressant + Placebo |
|---|---|---|
| Amphetamine Cessation Symptom Assessment (ACSA) - Total Aggregate Score | 17.0 ± 10.80 | 17.2 ± 10.56 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SPD489 | — | 1/211 (0.5%) | 72/211 (34.1%) |
| Placebo | — | 1/213 (0.5%) | 46/213 (21.6%) |
| Event | SPD489 | Placebo |
|---|---|---|
| Accelerated hypertensionVascular disorders | 1/211 | 0/213 |
| Suicidal ideationPsychiatric disorders | 0/211 | 1/213 |
| Event | SPD489 | Placebo |
|---|---|---|
| Dry mouthGastrointestinal disorders | 25/211 | 6/213 |
| HeadacheNervous system disorders | 25/211 | 16/213 |
| NasopharyngitisInfections and infestations | 14/211 | 19/213 |
| Decreased appetiteMetabolism and nutrition disorders | 13/211 | 5/213 |
| InsomniaPsychiatric disorders | 11/211 | 7/213 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 11/211 | 1/213 |
Safety Analysis Set: All subjects who took at least 1 dose of randomized investigational product and who had at least 1 safety assessment.
| Age, Continuous(Years) | Antidepressant + Double-blind SPD489 | Antidepressant + Double-blind Placebo | Total |
|---|---|---|---|
| Mean | 42 ± 11.63 | 42.6 ± 11.41 | 42.3 ± 11.51 |
| Age, Customized(Participants) | Antidepressant + Double-blind SPD489 | Antidepressant + Double-blind Placebo | Total |
|---|---|---|---|
| 18-55 years | 181 | 184 | 365 |
| 56-65 years | 30 | 29 | 59 |
| Sex: Female, Male(Participants) | Antidepressant + Double-blind SPD489 | Antidepressant + Double-blind Placebo | Total |
|---|---|---|---|
| Female | 141 | 143 | 284 |
| Male | 70 | 70 | 140 |
Showing the first 100 of 101 sites across 11 countries. Choose a country and city above to see the rest.
Ran from Oct 2011 to primary completion in Dec 2013, 25 months.
Results were first posted in Nov 2014, 10 months after primary completion. A results delay was requested in Aug 2014.
Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 25 months is close to that.
Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine